{"id":"NCT01908062","sponsor":"Oregon Health and Science University","briefTitle":"Comparing Treatments for HIV-Infected Opioid and Alcohol Users in an Integrated Care Effectiveness Study","officialTitle":"Comparing Treatments for HIV-Infected Opioid and Alcohol Users in an Integrated Care Effectiveness Study","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2014-06","primaryCompletion":"2015-03","completion":"2015-03","firstPosted":"2013-07-25","resultsPosted":"2019-02-26","lastUpdate":"2019-03-19"},"enrollment":51,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Opioid Use Disorder","Alcohol Use Disorder"],"interventions":[{"type":"DRUG","name":"Extended Release Naltrexone","otherNames":["Vivitrol"]},{"type":"OTHER","name":"Treatment As usual","otherNames":[]}],"arms":[{"label":"Treatment as Usual","type":"ACTIVE_COMPARATOR"},{"label":"Extended Release Naltrexone","type":"EXPERIMENTAL"}],"summary":"The purpose of this study is to learn how best to treat substance use disorders in an HIV clinic setting. Specifically, the purpose of this pilot study is to learn if extended-release naltrexone (XR-NTX) would be a feasible and acceptable treatment for HIV-infected individuals with opioid or alcohol use disorders.","primaryOutcome":{"measure":"Number of Participants With Successful Initiation of Treatment Within 4 Weeks of Randomization","timeFrame":"4 weeks","effectByArm":[{"arm":"Treatment as Usual","deltaMin":25,"sd":null},{"arm":"Extended Release Naltrexone","deltaMin":17,"sd":null}],"pValues":[]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":null,"exclusionCount":1},"locations":{"siteCount":2,"countries":["United States","Canada"]},"refs":{"pmids":["40342086","28061017"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":1,"n":26},"commonTop":["Nausea","Headache, Migraine","Vomiting","Diarrhea"]}}